A monoclonal antibody against estrogen stimulated leucine aminopeptidase
CA 2303505 C · Owner: Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health · Inventors: Pulido-Cejudo, Gabriel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The identification and characterization of risk factors and their molecular implications, in the pathophysiology of human diseases such as cancer is essential for designing, efficient diagnostic assays and therapeutic compounds. Estrogenic steroids under normal, physiological conditions have been shown to play a critical function in several tissues. The response of such a variety of tissues to estrogen stimulation can explain in part its, active role in the development and progression of different human diseases particularly, Breast Cancer. Searching for estrogen-responding cellular factors in parental cells of, primary human breast carcinomas obtained from tumour biopsies an isoenzyme …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 30, 2000 and granted November 13, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 30, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 30, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.